The emotional burden of caring for patients with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex-associated epilepsy: A qualitative study in Japan

被引:1
|
作者
LoPresti, Michael [1 ]
Igarashi, Ataru [2 ,3 ]
Sonohara, Yaoki [1 ]
Bowditch, Sally [4 ]
机构
[1] INTAGE Healthcare Inc, Value & Access Dept, Ochanomizu Sola City 13F,Kanda Surugadai 4-6,Chiyo, Tokyo 1010062, Japan
[2] Yokohama City Univ, Sch Med, Dept Publ Hlth, 22-2 Seto,Kanazawa ku, Yokohama, Kanagawa 2360027, Japan
[3] Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Hlth Econ & Outcomes Res, 7-3-1 Hongo,Bunkyo Ku, Tokyo 1130033, Japan
[4] Jazz Pharmaceut UK Ltd, Dept Patient Access & Value, Spires House,5700 John Smith Dr,Oxford Business Pk, Oxford OX4 2RW, England
关键词
Epilepsy; Lennox-Gastaut syndrome; Dravet syndrome; Tuberous sclerosis complex; Caregiver burden; Qualitative; MANAGEMENT; CAREGIVERS; DIAGNOSIS; FAMILIES; IMPACT;
D O I
10.1016/j.yebeh.2024.109932
中图分类号
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要
Introduction: Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS) are rare, childhood-onset conditions associated with severe, treatment-resistant epilepsy and developmental issues, including motor and cognitive impairment. Tuberous sclerosis complex (TSC) is a rare genetic disease commonly associated with epilepsy and other neuropsychiatric disorders. This cross-sectional, interview-based study examined the qualitative impact of caring for patients with LGS, DS, and TSC-associated epilepsy on caregivers in Japan, from the perspective of both caregivers and physicians. Methods: The survey included a pre-interview worksheet to describe caregivers' emotional journeys, followed by a <= 60-minute one-on-one interview. Eligible participants were Japanese caregivers of patients with LGS, DS, or TSC treated for epilepsy symptoms, and Japan-residing pediatricians or neurologists treating >= 3 patients with LGS, DS, and/or TSC. Interview question responses were subjected to content analysis to identify the most common response tendencies and themes. Results: Twenty-six caregivers responded (mean [standard deviation (SD)] age, 45.9 [9.5] years; age range 29-68; 92% female), caring for patients with LGS (n = 5), DS (n =10), and TSC (n = 11); patient mean (SD) age, 13.6 (10.0) years; age range 2-44; 27 % adults; 50 % female. Nineteen physicians, treating patients with LGS (n = 9), DS (n = 7), and TSC (n = 10), participated. Caregivers and physicians generally aligned on the factors affecting caregivers' emotional states / quality of life (QoL). The most frequently reported caregiver emotions at the time of diagnosis were shock and discouragement, anxiety for the future, and relief at receiving a diagnosis. Negative emotions throughout disease progression up until the time of survey were mainly caused by worsening of seizures, burden of constant caregiving / lack of free time, and patient's developmental issues. Positive emotions were linked to effective treatment / reduced seizures; more free time owing to the use of facilities, services, or other caregiving support; and developmental progress. Physicians acknowledged that caregivers required consultation services to support their emotional needs. In terms of unmet needs, caregiver and physician responses were aligned on the insufficient availability of services/facilities, the lack of effective treatments, and the uncertainties of adult patient care. Conclusions: Caregivers of patients with LGS, DS, or TSC-associated epilepsy in Japan reported a high degree of emotional burden related to frequent seizures, developmental issues, and constant caregiving. The burden of suboptimal treatment effectiveness, limited access to support services, and uncertainties in long-term care emphasize important unmet treatment needs.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Economic burden associated with tuberous sclerosis complex in patients with epilepsy
    Betts, Keith A.
    Stockl, Karen M.
    Yin, Lei
    Hollenack, Kelly
    Wang, Min-Jung
    Yang, Xiaoran
    EPILEPSY & BEHAVIOR, 2020, 112
  • [42] ECONOMIC BURDEN ASSOCIATED WITH TUBEROUS SCLEROSIS COMPLEX IN PATIENTS WITH EPILEPSY
    Betts, K. A.
    Stockl, K. M.
    Yin, L.
    Hollenack, K. A.
    Wang, M.
    VALUE IN HEALTH, 2020, 23 : S262 - S262
  • [43] Therapeutic outcome of patients with Lennox-Gastaut syndrome with mitochondrial respiratory chain complex I deficiency
    Na, Ji-Hoon
    Lee, Young-Mock
    FRONTIERS IN NEUROLOGY, 2024, 15
  • [44] Cannabidiol for Adjuvant Treatment of Seizures Associated with Lennox-Gastaut Syndrome and Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
    Wijnen, Ben
    Armstrong, Nigel
    Ramaekers, Bram
    Witlox, Willem
    Westwood, Marie
    Fayter, Debra
    Ryder, Steve
    Buksnys, Titas
    Worthy, Gill
    Misso, Kate
    Grimm, Sabine
    Kleijnen, Jos
    Joore, Manuela
    PHARMACOECONOMICS, 2020, 38 (10) : 1043 - 1053
  • [45] Healthcare Resource Burden of Selected Nonseizure Symptoms Among Patients With Lennox-Gastaut Syndrome (LGS) in the US
    Lu, M.
    Noman, A.
    Kumparatana, P.
    Taylor, K.
    Ma, X.
    Ip, Q.
    Wei, Y.
    Rao, S.
    ANNALS OF NEUROLOGY, 2025, 96 : S43 - S44
  • [46] Sulthiame add-on therapy in children with Lennox-Gastaut syndrome: A study of 44 patients
    Caraballo, Roberto H.
    Flesler, Santiago
    Reyes Valenzuela, Gabriela
    Fortini, Sebastian
    Chacon, Santiago
    Ross, Lucas
    Noli, Daniel
    SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, 2018, 62 : 55 - 58
  • [47] Cannabidiol (CBD) in patients with Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome (DS) on a Ketogenic Diet Therapy (KDT) in four phase 3 trials
    Cross, J. Helen
    Vyas, Kishan
    Sahebkar, Farhad
    Schreiber, Ashley
    Mazurkiewicz-Beldzinska, Maria
    EPILEPSIA, 2021, 62 : 269 - 270
  • [48] Time to Onset of Efficacy of Cannabidiol (CBD) During Titration in Patients with Lennox-Gastaut Syndrome and Dravet Syndrome Enrolled in Three Randomized Controlled Trials
    Mazurkiewicz-Beldzinska, Maria
    Privitera, Michael
    Marsh, Eric
    Villanueva, Vicente
    VanLandingham, Kevan
    Checketts, Daniel
    Knappertz, Volker
    NEUROLOGY, 2019, 92 (15)
  • [49] Long-term treatment effects of soticlestat in patients with Dravet syndrome or Lennox-Gastaut syndrome: interim data from the ENDYMION 1 trial
    Asgharnejad, M.
    Yao, Y.
    Dlugos, D.
    Mitra, P.
    Murthy, V.
    EPILEPSIA, 2023, 64 : 291 - 291
  • [50] Long-Term Treatment Effects of Soticlestat in Patients with Dravet Syndrome or Lennox-Gastaut Syndrome: Interim Data from the ENDYMION 1 Trial
    Yao, Yuan
    Dlugos, Dennis
    Asgharnejad, Mahnaz
    Mitra, Pranab
    Murthy, Venkatesha
    NEUROLOGY, 2023, 100 (17)